Device for detection of cellular stress

Patent metadata

Field	Value
Publication number	US-11692996-B2
Application number	US-202217839080-A
Country	US
Kind code	B2
Filing date	Jun 13, 2022
Priority date	Jun 14, 2021
Publication date	Jul 4, 2023
Grant date	Jul 4, 2023

Abstract

Disclosed is an assay for determining resistance in a target cell or tissue to a therapy associated with cellular stress using chemical microscopy and high-throughput single cell analysis to determine functional metabolic alteration, including determining metabolic reprogramming in a target cell or tissue to a therapy associated with cellular stress, and methods of using the assays.

First claim

We claim:

1. An assay for determining resistance in a target cell or tissue to a therapy associated with cellular stress, comprising,
measuring with chemical microscopy a functional metabolic change in the target cell or tissue, and
determining a metabolic index of resistance in the target cell or tissue to the therapy.

2. The assay of claim 1 , wherein the functional metabolic change comprises a change from glucose and glycolysis dependent anabolism and energy metabolism to fatty acid uptake and fatty acid oxidation dependent anabolism and energy metabolism.

3. The assay of claim 1 , wherein the metabolic index correlates to resistance to the therapy in the target cell or tissue when the functional metabolic change is a decrease in glucose and glycolysis dependent anabolism and an increase in fatty acid uptake and fatty acid oxidation dependent anabolism and energy metabolism.

4. The assay of claim 3 , wherein the metabolic index further correlates to resistance to the therapy in the target cell or tissue when the metabolic change is a decrease in de novo lipogenesis in the target cell or tissue.

5. The assay of claim 1 , wherein the metabolic index is a ratio of an increase in fatty acid uptake and oxidation to a decrease in glucose-dependent anabolism.

6. The assay of claim 1 , wherein measuring with chemical microscopy functional metabolic change comprises measuring glucose and glycolysis derived anabolism in the target cell or tissue, measuring fatty acid uptake and oxidation in the target cell or tissue, and determining a change from glucose anabolism in the target cell or tissue to fatty acid uptake and oxidation energy metabolism.

7. The assay of claim 6 , further comprising measuring de novo lipogenesis in the target cell or tissue, and determining a change from glucose and glycolysis dependent anabolism and de novo lipogenesis in the target cell or tissue to fatty acid uptake and oxidation energy metabolism.

8. The assay of claim 1 , wherein the chemical microscopy comprises Raman microscopy or infrared microscopy.

9. The assay of claim 1 , wherein the target cell induces cellular stress in the target cell or tissue.

10. The assay of claim 1 , wherein the cellular stress in the target cell or tissue is oxidative stress, metabolic stress, hypoxic stress, nutrient stress, thermal stress, genotoxic stress, or combinations thereof.

11. The assay of claim 1 , wherein the target cell or tissue is a cancer cell, and the therapy is a cancer therapy.

12. The assay of claim 11 , wherein the cancer therapy is selected from chemotherapy, radiotherapy, immunotherapy, targeted therapy, hormone therapy, light or laser therapy, photodynamic therapy, and combinations thereof.

13. The assay of claim 12 , wherein the chemotherapy is a platinum-based therapeutic selected from cisplatin, carboplatin, oxaliplatin, nedaplatin, and combinations thereof.

14. A method of treating or inhibiting resistance in a target cell or tissue to a therapy associated with cellular stress in a subject, comprising:
performing the assay of claim 1 to determine the metabolic index of resistance in the target cell or tissue to the therapy;
administering at least one inhibitor of fatty acid oxidation to the subject; and
administering at least one therapy to the subject.

15. The method of claim 14 , wherein measuring with chemical microscopy functional metabolic change comprises measuring glucose and glycolysis derived anabolism in the cancer cell, measuring fatty acid uptake and oxidation in the target cell or tissue, and the metabolic index is the ratio of an increase in fatty acid uptake and oxidation energy metabolism to a decrease in glucose and glycolysis derived anabolism in the target cell or tissue.

16. The method of claim 14 , wherein performing the assay of claim 1 further comprises obtaining a target cell or tissue from the subject.

17. The method of claim 14 , wherein the target cell is a cancer cell, and the therapy is a cancer therapy.

18. The method of claim 14 , wherein determining the metabolic index of resistance in the target cell or tissue to the therapy further includes a decrease in de novo lipogenesis.

19. The method of claim 14 , wherein fatty acid oxidation is inhibited in the target cell or tissue and the therapy induces cellular stress in the target cell or tissue, thereby inhibiting resistance to the therapy.

20. The method of claim 14 , wherein the at least one inhibitor of fatty acid oxidation is selected from etomoxir, oxfenicine, perhexiline, mildronate, trimetazidine, and combinations thereof.

Assignees

• Univ Boston
• Univ Northwestern

Inventors

• Cheng Ji-Xin
• Li Junjie
• Tan Yuying
• Matei Daniela
• Zhao Guangyuan

Classifications

• G01N33/48735

  Investigating suspensions of cells, e.g. measuring microbe concentration (by chemical means C12Q1/04; colony counters C12M1/34; concentration of particle suspensions in general G01N15/06) · CPC title

• G16H20/10

  relating to drugs or medications, e.g. for ensuring correct administration to patients · CPC title

• G01N27/416

  Systems (G01N27/27 takes precedence) · CPC title

• G01Q60/60

  SECM [Scanning Electro-Chemical Microscopy] or apparatus therefor, e.g. SECM probes · CPC title

• G01N27/30

  Electrodes, e.g. test electrodes; Half-cells (G01N27/414 takes precedence) · CPC title